Akari Secures Australian Patent for Core ADC Payload, Bolstering Global IP
AKTX sits 83% above its 52-week low of $3.25 on light trading volume (0.1× avg).
Summary
Akari Therapeutics announced it has secured Australian patent approval for its proprietary PH1 RNA splicing modulator ADC payload. This patent covers the core technology used in its antibody-drug conjugate (ADC) pipeline, including the lead candidate AKTX-101. This development significantly strengthens Akari's global intellectual property portfolio, building on recent positive preclinical data and abstract acceptance for AKTX-101. For a micro-cap biotech, robust IP protection is critical as it de-risks the company's assets and enhances its long-term valuation and potential for future partnerships. Investors will continue to monitor the progress of AKTX-101 through IND-enabling studies towards a planned Phase 1 clinical trial in late 2026/early 2027.
At the time of this announcement, AKTX was trading at $5.95 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.6M. The 52-week trading range was $3.25 to $59.60. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.